In relapsed acute myeloid leukaemia (AML), a phase I trial using Plerixafor demonstrated efficacy in overcoming stromal-leukaemia protection against targeted therapy, by mobilising CD34+CD38− leukaemia cells to the periphery [29]. This evidence concerns the gene CD38 and acute myeloid leukemia.